Study on the resistance cycle of pyrotinib/erenib

Pyrotinib Maleate (Pyrotinib Maleate) is a targeted therapy drug mainly used to treat HER2-positive breast cancer. As a tyrosine kinase inhibitor (TKI), pyrotinib exerts anti-tumor effects by inhibiting HER2 receptors and related signaling pathways. However, despite the significant clinical efficacy of pyrotinib, drug resistance remains a challenge that cannot be ignored during treatment.

The emergence of pyrotinib resistance is often associated with adaptive changes in tumor cells. The mechanism of drug resistance may involve HER2 receptor gene mutations, changes in kinase activity, or reactivation of other downstream signaling pathways. For example, HER2 mutations or other pathways related to cancer cell proliferation and survival (such as the PI3K/Akt or MAPK pathways) may become more active, causing drug treatments to be ineffective.

The current study found that resistance to pyrotinib may develop within a few months to a year of treatment, with this resistance cycle varying among individual patients. The specific timing and mechanisms of drug resistance development need to be further explored through larger-scale and long-term clinical studies. It is worth noting that drug resistance does not mean that treatment is completely ineffective. Some patients can still achieve certain effects by adjusting drug dosage or combining treatment with other drugs.

To overcome drug resistance, researchers are exploring multiple strategies, such as the combined use of other targeted drugs or immunotherapy, to improve the persistence and effectiveness of pyrotinib treatment. With a deeper understanding of the mechanisms of drug resistance, more novel treatment options may emerge, thereby extending the patient's tolerance period to pyrotinib and improving treatment efficacy.

Overall, as a targeted therapy drug, the effectiveness and safety of pyrotinib have been widely recognized. It is expected that in the future market, the price of pyrotinib will gradually become more affordable and become an acceptable treatment option for more patients.